Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
We reviewed clinical studies investigating the pharmacological treatment of major depressive episodes (MDEs) with mixed features diagnosed according to the dimensional criteria (more than two or three [hypo]manic symptoms+principle depressive symptoms). We systematically reviewed published randomized controlled trials on the pharmacological treatment of MDEs with mixed features associated with mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). We searched the PubMed, Cochrane Library, and ClinicalTrials.gov databases through December 2017 with the following key word combinations linked with the word OR: (a) mixed or mixed state, mixed features, DMX, mixed depression; (b) depressive, major depressive, MDE, MDD, bipolar, bipolar depression; and (c) antidepressant, antipsychotic, mood stabilizer, anticonvulsant, treatment, medication, algorithm, guideline, pharmacological. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We found few randomized trials on pharmacological treatments for MDEs with mixed features. Of the 36 articles assessed for eligibility, 11 investigated MDEs with mixed features in mood disorders: six assessed the efficacy of antipsychotic drugs (lurasidone and ziprasidone) in the acute phase of MDD with mixed features, although four of these were post hoc analyses based on large randomized controlled trials. Four studies compared antipsychotic drugs (olanzapine, lurasidone, and ziprasidone) with placebo, and one study assessed the efficacy of combination therapy (olanzapine+fluoxetine) in the acute phase of BD with mixed features. Pharmacological treatments for MDEs with mixed features have focused on antipsychotics, although evidence of their efficacy is lacking. Additional well-designed clinical trials are needed.
Abstract
We reviewed clinical studies investigating the pharmacological treatment of major depressive episodes (MDEs) with mixed features diagnosed according to the dimensional criteria (more than two or three [hypo]manic symptoms+principle depressive symptoms). We systematically reviewed published randomized controlled trials on the pharmacological treatment of MDEs with mixed features associated with mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). We searched the PubMed, Cochrane Library, and ClinicalTrials.gov databases through December 2017 with the following key word combinations linked with the word OR: (a) mixed or mixed state, mixed features, DMX, mixed depression; (b) depressive, major depressive, MDE, MDD, bipolar, bipolar depression; and (c) antidepressant, antipsychotic, mood stabilizer, anticonvulsant, treatment, medication, algorithm, guideline, pharmacological. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We found few randomized trials on pharmacological treatments for MDEs with mixed features. Of the 36 articles assessed for eligibility, 11 investigated MDEs with mixed features in mood disorders: six assessed the efficacy of antipsychotic drugs (lurasidone and ziprasidone) in the acute phase of MDD with mixed features, although four of these were post hoc analyses based on large randomized controlled trials. Four studies compared antipsychotic drugs (olanzapine, lurasidone, and ziprasidone) with placebo, and one study assessed the efficacy of combination therapy (olanzapine+fluoxetine) in the acute phase of BD with mixed features. Pharmacological treatments for MDEs with mixed features have focused on antipsychotics, although evidence of their efficacy is lacking. Additional well-designed clinical trials are needed.
참고문헌 (31)
- Akiskal HS, "Family history validation of the bipolar nature of depressive mixed states", J Affect Disord, 73, pp.113~122 (2003)
- Akiskal HS, "Validating Kraepelin's two types of depressive mixed states: “depression with flight of ideas“and” excited depression”", World J Biol Psychiatry, 5, pp.107~113 (2004)
- Benazzi F., "Depressive mixed states: unipolar and bipolar II", Eur Arch Psychiatry Clin Neurosci, 250, pp.249~253 (2000)
- Benazzi F, "Depressive mixed state: testing different definitions", Psychiatry Clin Neurosci, 55, pp.647~652 (2001)
- Benazzi F., "Mixed states in bipolar II disorder: should full hypomania always be required?", Psychiatry Res, 127, pp.247~257 (2004)
- Benazzi F, "Delineating bipolar II mixed states in the Ravenna-San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes", J Affect Disord, 67, pp.115~122 (2001)
- Shim IH, "Mixed-state bipolar I and II depression: time to remission and clinical characteristics", J Affect Disord, 152-154, pp.340~346 (2014)
- Ather Muneer, "Staging Models in Bipolar Disorder: A Systematic Review of the Literature", Clinical Psychopharmacology and Neuroscience, 14(2), pp.117~130 (2016), 대한정신약물학회
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders, 4th ed, text revision" (2000), American Psychiatric Association
- Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration", PLoS Med, 6, pp.e1000100~ (2009)
- Suppes T, "Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 173, pp.400~407 (2016)
- Tsai J, "Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study", CNS Spectr, 22, pp.236~245 (2017)
- Swann AC, "Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis", CNS Spectr, 22, pp.228~235 (2017)
- Sramek J, "Lurasidone in post-menopausal females with major depressive disorder with mixed features: post-hoc analysis of a placebo-controlled trial", Prog Neuropsychopharmacol Biol Psychiatry, 78, pp.12~17 (2017)
- Goldberg J, "Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response?", Neuropsychopharmacology, 41, pp.S515~S516 (2016)
- Patkar AA, "A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder", J Clin Psychopharmacol, 35, pp.319~323 (2015)
- Suppes T, "Mixed features in major depressive disorder:diagnoses and treatments", CNS Spectr, 22, pp.155~160 (2017)
- Benazzi F, "Olanzapine", fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis, 2009, pp.70, 1424~1431
- Tohen M, "Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features", J Affect Disord, 164, pp.57~62 (2014)
- McIntyre RS, "Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial", J Clin Psychiatry, 76, pp.398~405 (2015)
- Patkar A, "A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state", PLoS One, 7, pp.e34757~ (2012)
- Pae CU, "Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state", Pharmacopsychiatry, 45, pp.152~155 (2012)
- Muralidharan K, "Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials", J Affect Disord, 150, pp.408~414 (2013)
- Nelson C, "Lurasidone for major depressive disorder with mixed features: effect of baseline depression severity on clinical outcome", Eur Neuropsychopharmacol, 26, pp.S400~S401 (2016)
- Pikalov A, "Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response?", Eur Psychiatry, 41, pp.S243~ (2017)
- Stahl SM, "Guidelines for the recognition and management of mixed depression", CNS Spectr, 22, pp.203~219 (2017)
- Pae CU, "Mixed depression: a study of its phenomenology and relation to treatment response", J Affect Disord, 136, pp.1059~1061 (2012)
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- Hee Ryung Wang, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 15(3), pp.199~209 (2017), 대한정신약물학회[DOI]
- McIntyre RS, "Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder", J Clin Psychiatry, 78, pp.703~713 (2017)
- Houston JP, "Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes:a double-blind, placebo-controlled study", J Clin Psychiatry, 70, pp.1540~1547 (2009)